switching between glp-1 agonists Frontiers Capsule 61 - Therapeutic Interchange:

Semaglutide offers a longer track record of safety data and may suit those preferring a well-established therapy or experiencing GIP-related sensitivity

It is a once-daily subcutaneous injection

Individualized risk assessment, patient education, and prompt evaluation of persistent symptoms are essential to optimize treatment adherence and minimize potential clinical and economic consequences

The impact of GLP1 agonists on bone metabolism: A systematic review

If you or a loved one has been exposed to PFAS-contaminated water or products and has developed health issues, you may be eligible to file a PFAS lawsuit

8 Future directions The advancement of GLP-1 receptor agonists is progressing towards more refined treatment strategies, with tirzepatide at the forefront of research as a dual GIP/GLP-1 receptor agonist (Nauck and DAlessio 2022)